Towards an economic evidence base for pharmacogenetics: Consideration of outcomes in key

Pharmacogenomics

Volumn 9, Issue 1, 2008, Pages 1-4

  Payne, Katherine ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b The Nowgen Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; PURINE DERIVATIVE; THIOPURINE METHYLTRANSFERASE; METHYLTRANSFERASE;

CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; EDITORIAL; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE UTILIZATION; HUMAN; LEUKOPENIA; MEDICAL RESEARCH; NEUTROPENIA; PHARMACOGENETICS; PREDICTION; QUALITY ADJUSTED LIFE YEAR; ECONOMICS; FACTUAL DATABASE; GENETICS; HEALTH CARE PLANNING; ORGANIZATION; STATISTICS; TREATMENT OUTCOME; UNITED KINGDOM; UTILIZATION REVIEW;

COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; DECISION MAKING, ORGANIZATIONAL; EVIDENCE-BASED MEDICINE; GREAT BRITAIN; HEALTH RESOURCES; HUMANS; METHYLTRANSFERASES; PHARMACOGENETICS; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 40949133446     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.1.1     Document Type: Editorial

References (24)

1. The Royal Society: Personalised medicines: Hopes and Realities. London, UK (2005).
2. Fargher EA, Tricker K, Newman B et al.: Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase (TPMT) testing prior to azathioprine prescription. J. Clin. Pharm. Ther. 32, 187-195 (2007).
3. Grabinski JL: Pharmacogenomics of anticancer agents: implications for clinical pharmacy practice. J. Pharm. Prac. 20(3), 246-251 (2007).
4. Drummond M, Sculpher M, Torrance GW, O'Brien BJ, Stoddart G: Methods For the Economic Evaluation of Health Care Programmes. 3rd Revised Edition. Oxford University Press, Oxford, UK (2005).
5. National Institute for Health and Clinical Excellence: a Guide to Techhology Appraisals. NICE, London, UK (2004).
6. Dolan P: Modelling valuation for EuroQOL health states. Med. Care 35, 351-363 (1997).
7. Brazier J, Roberts J, Deverill M: The estimation of a preference-based measure of health from the SF-36. J. Health Econ. 21(2), 271-292 (2002).
8. Williams A: Economics of coronary artery bypass grafting. BMJ 291, 326-329 (1985).
9. Gafni A, Birch S: Preferences for outcomes in economic evaluation: an economic approach to addressing economic problems. Soc. Sci. Med. 40(6), 767-776 (1995).
10. Tsuchiya A, Dolan P: The QALY model and individual preferences for health states and health profiles over time: a systematic review of the literature. Med. Decis. Making 25, 460-467 (2005)
11. Payne K, Nicholls S, McAllister M et al.: Outcome measures for clinical genetics services: a comparison of genetics healthcare professionals and patients' views. Health Policy 84, 112-122 (2007).
12. Fargher EA, Eddy C, Newman W et al.: Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics 8(11), 1511-1519 (2007).
13. Elliott RA, Payne K: Essentials of Economic Evaluation in Health Care. The Pharmaceutical Press, London, UK (2005).
14. Smith R: Construction of the contingent valuation market in health care: a critical assessment. Health Economics 12, 609-628 (2003).
15. Phillips KA, Van Bebber SL: A systematic review of cost-effectiveness analysis of pharmacogenomic interventions. Pharmacogenomics 5 (8), 1139-1149 (2004).
16. Rogowski W: Current impact of gene technology on healthcare. A map of economic assessments. Health Policy 80(2), 340-357 (2007).
17. Marra CA, Esdaile JM, Anis AH: Practical pharmacogenetics: the cost effectiveness of screening for thiopurine S-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J. Rheumatol. 29(12), 2507-2512 (2002).
18. Winter J, Walker A, Shapiro D, Gaffney D, Spooner RJ, Mills PR: Cost-effectiveness of thlopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 20(6), 593-599 (2004).
19. Oh KT, Anis AH, Bae SC: Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. Rheumatology 43(2), 156-163 (2004).
20. Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ: A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am. J. Gastro. 100(10), 2239-2247 (2005).
21. Priest VL, Begg EJ, Gardiner SJ et al.: Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics 24(8), 767-781 (2006).
22. van den Akker-van Marle ME, Gurwitz D, Detmar SB et al.: Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 7(5), 783-792 (2006).
23. Phillips KA, Veenstra D, Van Bebber SL, Sakowski J: An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics. Pharmacogenomics 4(3), 231-239 (2003).
24. Flowers CR, Veenstra D: The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoecnomics 22(8), 481-493 (2004).